Biotech Values

[DewDiligence]

IDIX 2008-2009 Clinical Goals

[New disclosure (at BofA conference) on planned data release of IDX184 PoC study at EASL 2009.]


HIV / IDX899

Sep 2008: Report final IDX184 PK/PD monotherapy data for 100mg dose. (Data on 200, 400, and 800mg doses were reported in June: #msg-29959114).

Late 2008: Start phase-2 PoC combination study (IDX899+Truvada vs Sustiva+Truvada) in first- and second-line patients.

Late 2008: Partner IDX899 program. (Please see #msg-28959639 for musings on the terms of such a partnership). JP Sommadossi has said that IDIX is in “advanced discussions with two different groups,” neither of which is NVS.


HCV

Fall 2008: Complete IDX184 SAD study in healthy volunteers and start 3-day monotherapy study in HCV patients.

Late 2008/early 2009: Start PoC combination study of IDX184 with pef-ifn and ribavirin.

April 2009: Report preliminary results of IDX184 PoC study at EASL.

1H09: File IND for IDX136 and IDX316 protease inhibitors.

1H09: File IND for IDX375 non-nucleoside polymerase inhibitor.